NASDAQ
5.32USD
+0.21 (+4.22%)
We have scored 34 news catalysts on Alvotech (ALVO) over the past 12 months. The biggest single-day move next to one of them came Dec 25, 2025, when ALVO closed +10.0%: “Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO”. Coverage across the window leans negative (average ticker sentiment −0.44). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
0.18
52W range
2.94-9.25
Day range
5.20–5.39
Open
5.25
Prev close
5.10
Volume
565.1K
Avg volume
863K
Dividend
0.00
IPO
2022-06-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Alvotech — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Alvotech, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ALVO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
